*Infectious Agents and Disease*
2:398 © 1994 Raven Press, Ltd., New York

# Infectious Agents and Disease
# Volume 2, 1993

## Author Index

Alter MJ, 155
Arnqvist A, 272
Arvin AM, 375

Barzu O, 210
Berger KH, 220
Beverley SM, 25
Bloom BR, 232, 259, 282
Boothroyd JC, 100
Burton DR, 118

Camilli A, 263
Cao C, 193
Chanock RM, 118
Clark-Curtiss JE, 279
Cohen D, 193
Collins FM, 282
Corriveau CC, 35, 44
Cossart P, 207
Crowe JE, Jr, 118

Dambaugh TR, 343
Danner RL, 35, 44
Davis GL, 150
De Gruttola V, 304
Denkers EY, 139

Eckmann L, 255
Elder JH, 361

Falkow S, 167
Fierer J, 255
Finlay BB, 227
Flak TA, 173
Flynn JAL, 259
Forsberg A, 275

Galán JE, 288
Garcia-del Portillo F, 227
Gazzinelli RT, 139
Gelman R, 304
Giannasca PJ, 242
Goldberg MB, 210
Goldman WE, 169, 173
Goldstein MM, 259
Gubler DJ, 383

Hammar M, 272
Hanna PC, 263
Harding CV, 249
Heiss LN, 173
Hickman S, 193
Hiltbold EM, 314
Holland IB, 212
Horwitz SB, 193

Inoue N, 343
Isberg RR, 220, 224, 269

Jacobs WR, Jr., 282
Joiner KA, 215

Kagnoff M, 255
Kenny B, 212
King CL, 103
Kiyono H, 55
Kocks C, 207
Kress Y, 232

Lagakos S, 304
Laimins LA, 74
Lancaster JR, Jr., 173
Leung KY, 227
Lim H, 150

Mahan MJ, 263
Martin JM, 282
Mawle AC, 333
McDaniel ML, 173
McDonough KA, 232
McGhee JR, 55
Medina-Acosta E, 25
Mekalanos JJ, 263
Mellman I, 186
Miller VL, 236, 288
Moss A, 132
Moulder JW, 87
Murphy BR, 118

Neu HC, 193
Neutra MR, 242
Normark S, 272
Normark SJ, 249
Nutman TB, 103

Olsén A, 272

Parsot C, 210
Pascopella L, 282
Pellett PE, 343
Pepe JC, 236
Pettinelli CB, 291
Pfeifer JD, 249
Phillips TR, 361
Plum G, 279
Portnoy D, 183, 288
Prevost MC, 212
Prober CG, 375

Rankin S, 220, 269
Reyes M, 333
Rhen M, 285
Riikonen P, 285
Roos RP, 342
Rosqvist R, 275
Roy CR, 220
Russell DG, 25

Sansonetti PJ, 201, 210, 212
Schaechter M, 394
Schmid DS, 333
Schnittman SM, 291
Segal ED, 178
Seong BL, 17
Sher A, 139
Silverstein SC, 193
Slauch JM, 263
Small PM, 132
Smith GA, 183
St. Geme, JW, III, 1
Steinberg TH, 193
Stringer JR, 109
Swanson MS, 220, 224

Taira S, 285
Tobias JW, 263
Tompkins LS, 178
Trent DW, 383
Triebold KJ, 259

Waldor MK, 263
Wenger JD, 324
Wick MJ, 249

Ziegler HK, 314
Zwick MB, 227
Zychlinsky A, 212

*Infectious Agents and Disease*
2:398 © 1994 Raven Press, Ltd., New York

# Infectious Agents and Disease
# Volume 2, 1993

## Author Index

Alter MJ, 155
Arnqvist A, 272
Arvin AM, 375

Barzu O, 210
Berger KH, 220
Beverley SM, 25
Bloom BR, 232, 259, 282
Boothroyd JC, 100
Burton DR, 118

Camilli A, 263
Cao C, 193
Chanock RM, 118
Clark-Curtiss JE, 279
Cohen D, 193
Collins FM, 282
Corriveau CC, 35, 44
Cossart P, 207
Crowe JE, Jr, 118

Dambaugh TR, 343
Danner RL, 35, 44
Davis GL, 150
De Gruttola V, 304
Denkers EY, 139

Eckmann L, 255
Elder JH, 361

Falkow S, 167
Fierer J, 255
Finlay BB, 227
Flak TA, 173
Flynn JAL, 259
Forsberg A, 275

Galán JE, 288
Garcia-del Portillo F, 227
Gazzinelli RT, 139
Gelman R, 304
Giannasca PJ, 242
Goldberg MB, 210
Goldman WE, 169, 173
Goldstein MM, 259
Gubler DJ, 383

Hammar M, 272
Hanna PC, 263
Harding CV, 249
Heiss LN, 173
Hickman S, 193
Hiltbold EM, 314
Holland IB, 212
Horwitz SB, 193

Inoue N, 343
Isberg RR, 220, 224, 269

Jacobs WR, Jr., 282
Joiner KA, 215

Kagnoff M, 255
Kenny B, 212
King CL, 103
Kiyono H, 55
Kocks C, 207
Kress Y, 232

Lagakos S, 304
Laimins LA, 74
Lancaster JR, Jr., 173
Leung KY, 227
Lim H, 150

Mahan MJ, 263
Martin JM, 282
Mawle AC, 333
McDaniel ML, 173
McDonough KA, 232
McGhee JR, 55
Medina-Acosta E, 25
Mekalanos JJ, 263
Mellman I, 186
Miller VL, 236, 288
Moss A, 132
Moulder JW, 87
Murphy BR, 118

Neu HC, 193
Neutra MR, 242
Normark S, 272
Normark SJ, 249
Nutman TB, 103

Olsén A, 272

Parsot C, 210
Pascopella L, 282
Pellett PE, 343
Pepe JC, 236
Pettinelli CB, 291
Pfeifer JD, 249
Phillips TR, 361
Plum G, 279
Portnoy D, 183, 288
Prevost MC, 212
Prober CG, 375

Rankin S, 220, 269
Reyes M, 333
Rhen M, 285
Riikonen P, 285
Roos RP, 342
Rosqvist R, 275
Roy CR, 220
Russell DG, 25

Sansonetti PJ, 201, 210, 212
Schaechter M, 394
Schmid DS, 333
Schnittman SM, 291
Segal ED, 178
Seong BL, 17
Sher A, 139
Silverstein SC, 193
Slauch JM, 263
Small PM, 132
Smith GA, 183
St. Geme, JW, III, 1
Steinberg TH, 193
Stringer JR, 109
Swanson MS, 220, 224

Taira S, 285
Tobias JW, 263
Tompkins LS, 178
Trent DW, 383
Triebold KJ, 259

Waldor MK, 263
Wenger JD, 324
Wick MJ, 249

Ziegler HK, 314
Zwick MB, 227
Zychlinsky A, 212

*Infectious Agents and Disease*
2:399–403 © 1994 Raven Press, Ltd., New York

# Infectious Agents and Disease
# Volume 2, 1993

## Subject Index

Actin
  polymerization by *Listeria monocytogenes*, 207
Adenylate cyclase toxin
  and target cell interactions, 169
*Aedes aegypti*
  dengue/dengue hemorrhagic fever, epidemic in Americas, 383
AIDS
  CD4 lymphocytes in treatment decisions, 304
  host resistance to *Toxoplasma gondii*, 139
  *Pneumocystis carinii* as fungi, 109
  treatment research priorities for HIV infection, 291
Animal studies
  *Bordetella pertussis* tracheal cytotoxin damage, role of nitric oxide, 173
  endotoxin as therapeutic target in septic shock, 35, 44
  host resistance to *Toxoplasma gondii*, 139
  major histocompatibility complex class I-restricted T cells in protection from *Mycobacterium tuberculosis*, 259
  *Mycobacterium tuberculosis* virulence genes, 282
  *Pneumocystis carinii* as fungi, 109
  *Yersinia enterocolitica* infection, invasin role, 236
  *Yersinia pseudotuberculosis* virulence genes, 275
Anogenital cancer
  human papillomavirus, 74
Antibodies
  antiendotoxin therapy, in septic shock, 35, 44
  human monoclonal Fab fragments, in immunotherapy, 118
Antigens
  of feline immunodeficiency virus, 361
  intestinal M cells, interaction with microorganisms, 242
  of *Listeria monocytogenes*, 314
  macrophage phagocytosis of intact bacteria, T cell epitopes, 249
  mucosal immunity to infections, in vaccine development, 55
Antiretroviral compounds
  for HIV infection, treatment research priorities, 291
ATPase
  in *Shigella flexneri*, IcsA activity in intracellular movement, 210

Bacteria
  entry into eukaryotic cells, in vitro and in vivo assays, 288
  *See also* specific bacteria.
Bacterial-host cell interactions
  Bristol-Myers Squibb symposium, Infectious Disease Research, 167-288
Binding sites
  endotoxin, in septic shock, 35, 44
Book Review
  *Infectious Diseases of the Central Nervous System*, 342
*Bordetella pertussis*
  tracheal cytotoxin damage, role of nitric oxide, 173
Brazilian purpuric fever
  nontypeable *Haemophilus influenzae* disease, 1

Cancer
  human papillomavirus, 74
CD4 lymphocytes
  in AIDS treatment decisions, 304
Cell-mediated immunity
  host resistance to *Toxoplasma gondii*, 139
Children and infants
  hepatitis C virus transmission, 155
  herpes simplex virus infections, glycoprotein G antibody assay, 375
  neonatal sepsis, nontypeable *Haemophilus influenzae* disease, 1
*Chlamydia*
  sensitivity to penicillin in absence of peptidoglycan, 87
Cholera toxin
  in mucosal immunity to infections, in vaccine development, 55
Chronic fatigue syndrome
  as infectious disease, 333
Classification
  nontypeable *Haemophilus influenzae* disease, 1
Clinical studies
  CD4 lymphocytes in AIDS treatment decisions, 304
  endotoxin as therapeutic target in septic shock, 35, 44
  herpes simplex virus infection in pregnant women and infants, glycoprotein G antibody assay, 375
  human monoclonal antibody Fab fragments, in immunotherapy, 118
  interferon therapy for chronic hepatitis C, 150
Clonality
  of human monoclonal antibody Fab fragments, 118
  of *Toxoplasma*, 100

Conjunctivitis
nontypeable *Haemophilus influenzae* disease, 1
Curli
in *Escherichia coli*, 272
Curriculum
teaching microbiology to medical students, 394
Cytokines
antigen processing and presentation of *Listeria monocytogenes*, 314
in chronic fatigue syndrome, 333
in helminth infections, 103
Cytomegalovirus
human monoclonal antibody Fab fragments, in immunotherapy, 118

Dengue
and dengue hemorrhagic fever, epidemic in Americas, 383
DNA
of human herpesviruses 6A and 6B, 343
human papillomavirus, 74
papillomavirus, in warts to cancer, 74
Drug resistance
molecular epidemiology of tuberculosis, 132
probenecid-resistant J774 cell expression of organic anion transport, 193

Education
microbiology teaching to medical students, 394
Endocytosis
antigen processing and presentation of *Listeria monocytogenes*, 314
and entry of intracellular parasites, 186
Endotoxin
in septic shock, 35, 44
and target cell interactions, 169
Environment
extraintestinal, curli production by *Escherichia coli*, 272
Eosinophilia
in helminth infections, cytokines and immediate hypersensitivity, 103
Epidemiology
bacterial meningitis, *Hemophilus influenzae* type b vaccines, 324
chronic fatigue syndrome as infectious disease, 333
hepatitis C virus infection, 155
herpes simplex virus infection in pregnant women and infants, 375
molecular, of tuberculosis, 132
nontypeable *Haemophilus influenzae* disease, 1
*Yersinia enterocolitica* infection, invasin role, 236
Epithelium
bacterial invasion, IL-8 secretion, 255
molecular and cellular *Shigella flexneri* invasion, 201
*Salmonella* replication, 227
*Escherichia coli*
curli production, 272

Eubacteria
wall-less, *Chlamydia* sensitivity to penicillin in absence of peptidoglycan, 87

Fab fragments
human monoclonal antibodies, in immunotherapy, 118
Feline immunodeficiency virus (FIV)
molecular properties, 361
Fimbrin
in actin polymerization by *Listeria monocytogenes*, 207
Fungi
*Pneumocystis carinii* phylogenetics, 109

Gene expression
bacterial, in host tissues, virulence factors, 263
curli in *Escherichia coli*, 272
by feline immunodeficiency virus, 361
*ipaB* of *Shigella flexneri*, in cell death, 212
*Leishmania* surface proteinase (gp63), 25
*Mycobacterium avium*, in human macrophages, 279
*Mycobacterium tuberculosis* virulence, 282
phospholipases in *Listeria monocytogenes* pathogenicity, 183
*Salmonella typhimurium* virulence in macrophages, 285
*Yersinia pseudotuberculosis* virulence, 275
Genetics
of influenza virus, 17
Genital tract
female, nontypeable *Haemophilus influenzae* disease, 1
Glycoproteins
antibody assay, herpes simplex virus infections in pregnant women and infants, 375
of human herpesviruses 6A and 6B, 343
lysosomal membrane, in *Salmonella* replication in epithelial cells, 227

*Haemophilus influenzae*
nontypeable disease, epidemiology, pathogenesis and prevention of, 1
Heat-labile toxin
and target cell interactions, 169
*Helicobacter pylori*
hemolysin characterization, 178
Helminth infections
cytokines and immediate hypersensitivity, 103
Hemolysin
of *Helicobacter pylori*, 178
*Hemophilus influenzae*
type b vaccines, and bacterial meningitis, 324
Hepatitis B virus
human monoclonal antibody Fab fragments, in immunotherapy, 118
Hepatitis C virus
epidemiology of chronic infection, 155
interferon therapy, 150

Herpes simplex virus
infection in pregnant women and infants, glycoprotein G antibody assay, 375
Herpesviruses
6A and 6B, molecular biology of, 343
Household exposure
hepatitis C virus transmission, 155
Human herpesviruses
6A and 6B, molecular biology of, 343
Human immunodeficiency virus
human monoclonal antibody Fab fragments, in immunotherapy, 118
treatment research priorities, 291
Human monoclonal antibody
Fab fragments, in immunotherapy, 118
Human papillomavirus
in warts to cancer, 74
Hypersensitivity
immediate, in helminth infections, 103

IcsA
ATPase activity, in *Shigella flexneri*, 210
Immunoglobulin A (IgA)
in microorganism interaction with intestinal M cells, 242
mucosal immunity to infections, in vaccine development, 55
Immunoglobulin E (IgE)
helminth infections, cytokines and immediate hypersensitivity, 103
Immunoglobulin G (IgG)
endocytosis and intracellular parasites, 186
Immunotherapy
HIV infection, treatment research priorities, 291
host resistance to *Toxoplasma gondii*, 139
human monoclonal antibody Fab fragments, 118
interferon for chronic hepatitis C, 150
Infants. *See* Children and infants.
Infection
chronic fatigue syndrome, 333
dengue/dengue hemorrhagic fever, epidemic in Americas, 383
helminth, cytokines and immediate hypersensitivity, 103
hepatitis C virus, 155
HIV, treatment research priorities, 291
*M. tuberculosis*, major histocompatibility complex class I-restricted T cells, 259
molecular epidemiology of tuberculosis, 132
mucosal immunity, in vaccine development, 55
by *Yersinia enterocolitica*, invasin role, 236
Influenza virus
genetic analysis, negative-sense RNA genome, 17
Interferon
for chronic hepatitis C, 150
Interferon-gamma
in host resistance to *Toxoplasma gondii*, 139
Interleukin-8 (IL-8)
in bacterial invasion of epithelial cells, 255
Intestine
bacterial invasion of epithelial cells, IL-8 secretion, 255
M cell interaction with microorganisms, 242
Invasin
in *Yersinia enterocolitica* infection, 236
*ipaB* gene
of *Shigella flexneri*, in cell death, 212
IVET (in vivo expression technology)
virulence factors, bacterial genes in host tissues, 263

*Legionella pneumophila*
intracellular replication, 220, 224
promoters, macrophage intracellular environment, 269
*Leishmania*
surface proteinase (gp63) gene locus, 25
vacuolar membranes, 215
Lipid A analogues
antiendotoxin therapy, in septic shock, 35, 44
*Listeria monocytogenes*
actin polymerization, 207
antigen processing and presentation, 314
phospholipases in pathogenicity of, 183
Lung disease
nontypeable *Haemophilus influenzae* disease, 1
Lymphocytes
CD4, in AIDS treatment decisions, 304
in chronic fatigue syndrome, 333
Lymphocytic choriomeningitis virus
human monoclonal antibody Fab fragments, in immunotherapy, 118
Lysosomes
membrane glycoproteins, in *Salmonella* replication in epithelial cells, 227

M cells
bacterial entry into eukaryotic cells, in vitro and in vivo assays, 288
intestinal, interaction with microorganisms, 242
Macrophages
bacterial entry into eukaryotic cells, in vitro and in vivo assays, 288
cell death, *ipaB* gene of *Shigella flexneri*, 212
in host resistance to *Toxoplasma gondii*, 139
human, *Mycobacterium avium* gene expression, 279
*Legionella pneumophila* promoters, 269
*Mycobacterium tuberculosis* interaction, 232
phagocytosis of intact bacteria, T cell epitopes, 249
probenecid-resistant J774 cell expression of organic anion transport, 193
*Salmonella typhimurium* virulence plasmid genes, 285
Major histocompatibility complex
class I-restricted T cells, protection from *Mycobacterium tuberculosis*, 259
Mast cells
in helminth infections, cytokines and immediate hypersensitivity, 103
Medical students
microbiology teaching, 394
Membranes
vacuolar, around intracellular pathogens, 215

Meningitis
bacterial, *Hemophilus influenzae* type b vaccines, 324
nontypeable *Haemophilus influenzae* disease, 1
Microbiology
teaching of, to medical students, 394
Microorganisms
in intestinal M cells, 242
Molecular biology
bacterial-host cell interactions, Bristol-Myers Squibb symposium, Infectious Disease Research, 167-288
of feline immunodeficiency virus, 361
of human herpesviruses 6A and 6B, 343
Molecular genetics
of *Pneumocystis carinii*, 109
Mosquito
dengue/dengue hemorrhagic fever, epidemic in Americas, 383
Mucosa
bacterial invasion of epithelial cells, IL-8 secretion, 255
immunity to infections, in vaccine development, 55
intestinal M cells, interaction with microorganisms, 242
*Mycobacterium avium*
gene expression, in human macrophages, 279
*Mycobacterium tuberculosis*
genomic fragment, virulence genes, 282
interaction with macrophages, 232
major histocompatibility complex class I-restricted T cells in protection, 259
Mycoplasmas
penicillin sensitivity in absence of peptidoglycan, 87

Natural killer cells
in chronic fatigue syndrome, 333
in host resistance to *Toxoplasma gondii*, 139
Neoplasia
human papillomavirus, 74
Nitric oxide
and *Bordetella pertussis* tracheal cytotoxin damage, 173
Nomenclature
*Pneumocystis carinii* as fungi, 109

Organic anion transport
probenecid-resistant J774 cell expression, 193
Otitis media
nontypeable *Haemophilus influenzae* disease, 1

p53 regulator
human papillomavirus, 74
Papillomavirus
in warts to cancer, 74
Parasites
intracellular, and endocytosis, 186
Pathogens, intracellular
*Legionella pneumophila* replication, 220, 224
vacuolar membranes, 215
*See also* specific pathogens.
Penicillin
*Chlamydia* sensitivity to, in absence of peptidoglycan, 87
Peptidoglycan
absence in *Chlamydia*, and penicillin sensitivity, 87
Pertussis toxin
and target cell interactions, 169
Phage
surface expression, human monoclonal antibody Fab fragments, in immunotherapy, 118
Phagocytosis
endocytosis and intracellular parasites, 186
of intact bacteria by macrophages, T cell epitopes, 249
Phagosomes
intracellular *Legionella pneumophila*, 220, 224
*Mycobacterium tuberculosis* interaction with macrophages, 232
Phospholipases
in *Listeria monocytogenes* pathogenicity, 183
*Planctomyces*
penicillin sensitivity in absence of peptidoglycan, 87
*Pneumocystis carinii*
molecular genetics of, as diverse fungi, 109
Pneumonia
nontypeable *Haemophilus influenzae* disease, 1
Polysaccharides
in mucosal immunity to infections, in vaccine development, 55
Population biology
of *Toxoplasma*, 100
Pregnancy
herpes simplex virus infections, glycoprotein G antibody assay, 375
Probenecid
J774 cell expression of organic anion transport, 193
Promoters
influenza virus, negative-sense RNA genome, 17
Prophylaxis
human monoclonal antibody Fab fragments, 118
Protease inhibitors
for HIV infection, treatment research priorities, 291
Proteins
endotoxin binding, in septic shock, 35, 44
of feline immunodeficiency virus, 361
in mucosal immunity to infections, in vaccine development, 55

Replication, intracellular
*Legionella pneumophila*, 220, 224
*Salmonella* in epithelial cells, 227
Respiratory syncytial virus
human monoclonal antibody Fab fragments, in immunotherapy, 118
Restriction fragment length polymorphism
molecular epidemiology of tuberculosis, 132
Retinoblastoma
human papillomavirus, 74
Reverse transcriptase inhibitors
for HIV infection, treatment research priorities, 291

Risk factors
hepatitis C virus, 155
RNA
negative-sense genome, influenza virus, 17

*Salmonella typhimurium*
intracellular replication in epithelial cells, 227
virulence plasmid genes in macrophages, 285
Scrub typhus agent
penicillin sensitivity in absence of peptidoglycan, 87
Septic shock
endotoxin as therapeutic target, 35, 44
Sexual transmission
hepatitis C virus, 155
*Shigella flexneri*
ATPase activity of IcsA in intracellular movement, 210
*ipaB* gene in cell death, 212
molecular mechanisms of cell and tissue invasion, 201
Sinusitis
nontypeable *Haemophilus influenzae* disease, 1
Surface proteinase
*Leishmania* gp63 gene locus, 25
Symposium
Bristol-Myers Squibb, Infectious Disease Research, 167-288

T cells
antigen processing and presentation of *Listeria monocytogenes*, 314
in chronic fatigue syndrome, 333
epitopes, after phagocytosis of intact bacteria by macrophages, 249
epitopes, antigen processing and presentation of *Listeria monocytogenes*, 314
in host resistance to *Toxoplasma gondii*, 139
major histocompatibility complex class I-restricted, in protection from *Mycobacterium tuberculosis*, 259
mucosal immunity to infections, in vaccine development, 55
Tat antagonists
for HIV infection, treatment research priorities, 291
Taxonomy
*Pneumocystis carinii* as fungi, 109
Tetanus toxoid
in mucosal immunity to infections, in vaccine development, 55
Tissue culture
bacterial entry into eukaryotic cells, in vitro and in vivo assays, 288
Tolerance
in helminth infections, cytokines and immediate hypersensitivity, 103
Toxins
bacterial, and target cell interactions, 169
*Bordetella pertussis* tracheal cytotoxin damage, role of nitric oxide, 173
*Toxoplasma gondii*
host resistance, cell-mediated immunity, 139
population biology, 100
vacuolar membranes, 215
Tracheal cytotoxin
of *Bordetella pertussis*, role of nitric oxide, 173
and target cell interactions, 169
Transfection
hepatitis C virus, 155
negative-sense RNA genome, influenza virus, 17
virulence factors, bacterial genes in host tissues, 263
Tuberculosis
molecular epidemiology, 132
Tumor necrosis factor
in host resistance to *Toxoplasma gondii*, 139

Vaccines
*Hemophilus influenzae* type b, and bacterial meningitis, 324
influenza virus, genetic analysis, negative-sense RNA genome, 17
mucosal immunity to infections, 55
nontypeable *Haemophilus influenzae* disease, 1
Virulence
bacterial genes in host tissues, 263
*Mycobacterium tuberculosis* genes, 282
*Salmonella typhimurium* plasmid genes in macrophages, 285
of *Toxoplasma*, 100
*Yersinia pseudotuberculosis* genes, 275
Virus
influenza, genetic analysis, negative-sense RNA genome, 17
papillomavirus, in warts to cancer, 74
*See also* specific viruses.

Warts
human papillomavirus, 74

*Yersinia enterocolitica*
invasin role in infection, 236
*Yersinia pseudotuberculosis*
virulence genes, 275